230 related articles for article (PubMed ID: 22421313)
1. Prostate cancer stem cells.
Tu SM; Lin SH
Clin Genitourin Cancer; 2012 Jun; 10(2):69-76. PubMed ID: 22421313
[TBL] [Abstract][Full Text] [Related]
2. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
3. Early human prostate adenocarcinomas harbor androgen-independent cancer cells.
Fiñones RR; Yeargin J; Lee M; Kaur AP; Cheng C; Sun P; Wu C; Nguyen C; Wang-Rodriguez J; Meyer AN; Baird SM; Donoghue DJ; Haas M
PLoS One; 2013; 8(9):e74438. PubMed ID: 24086346
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer stem cells: are they androgen-responsive?
Oldridge EE; Pellacani D; Collins AT; Maitland NJ
Mol Cell Endocrinol; 2012 Sep; 360(1-2):14-24. PubMed ID: 21802490
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
7. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer.
Pfeiffer MJ; Smit FP; Sedelaar JP; Schalken JA
Mol Med; 2011; 17(7-8):657-64. PubMed ID: 21365123
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
[TBL] [Abstract][Full Text] [Related]
9. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors.
Rouet V; Bogorad RL; Kayser C; Kessal K; Genestie C; Bardier A; Grattan DR; Kelder B; Kopchick JJ; Kelly PA; Goffin V
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15199-204. PubMed ID: 20699217
[TBL] [Abstract][Full Text] [Related]
10. The many ways to make a luminal cell and a prostate cancer cell.
Strand DW; Goldstein AS
Endocr Relat Cancer; 2015 Dec; 22(6):T187-97. PubMed ID: 26307022
[TBL] [Abstract][Full Text] [Related]
11. Stem cells in genetically-engineered mouse models of prostate cancer.
Shibata M; Shen MM
Endocr Relat Cancer; 2015 Dec; 22(6):T199-208. PubMed ID: 26341780
[TBL] [Abstract][Full Text] [Related]
12. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.
Sharifi N; Kawasaki BT; Hurt EM; Farrar WL
Cancer Biol Ther; 2006 Aug; 5(8):901-6. PubMed ID: 16855379
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
Cai C; Wang H; Xu Y; Chen S; Balk SP
Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer stem cells: from theory to practice.
Adamowicz J; Pakravan K; Bakhshinejad B; Drewa T; Babashah S
Scand J Urol; 2017 Apr; 51(2):95-106. PubMed ID: 28635565
[TBL] [Abstract][Full Text] [Related]
16. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.
Dai B; Chen H; Guo S; Yang X; Linn DE; Sun F; Li W; Guo Z; Xu K; Kim O; Kong X; Melamed J; Qiu S; Chen H; Qiu Y
Cancer Res; 2010 Jul; 70(13):5587-96. PubMed ID: 20570899
[TBL] [Abstract][Full Text] [Related]
17. Androgen action and metabolism in prostate cancer.
Green SM; Mostaghel EA; Nelson PS
Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
[TBL] [Abstract][Full Text] [Related]
18. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
19. [Molecular mechanisms involved in hormone resistance of prostate cancer].
Cabrespine A; Guy L; Chollet P; Debiton E; Bay JO
Bull Cancer; 2004 Oct; 91(10):747-57. PubMed ID: 15556875
[TBL] [Abstract][Full Text] [Related]
20. Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer.
Boormans JL; Hermans KG; Made AC; van Leenders GJ; Wildhagen MF; Collette L; Schröder FH; Trapman J; Verhagen PC
Eur Urol; 2010 May; 57(5):830-5. PubMed ID: 19716227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
